Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00475553 · ClinicalTrials.gov registry record · NA
Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing®
A NA study of Breakthrough Bleeding and Breakthrough Spotting, sponsored by Scott and White Hospital & Clinic.
- Completed
- Registry status
- NA
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT00475553 is a NA study of Breakthrough Bleeding and Breakthrough Spotting that has completed, run by Scott and White Hospital & Clinic. The registered enrollment target is 75 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00475553, a NA study of Breakthrough Bleeding and Breakthrough Spotting, has completed, sponsored by Scott and White Hospital & Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to evaluate the best way to manage breakthrough spotting and bleeding during an extended use regimen of NuvaRing®. Ease of use and acceptability of a flexible regimen of NuvaRing® will also be evaluated. A comparison of cyclic mood symptoms, pelvic pain, and headaches will be made between a standard 21/7 regimen and an extended regimen.
Conditions Studied
Interventions
- OTHER remove ring if bleeding or spotting occurs more than 5 days
- OTHER If bleeding does not remove ring
Study Locations (1)
Texas
- Scott & White Hospital and Clinic - Temple
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00475553
The ClinicalTrials.gov registry entry for NCT00475553 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scott and White Hospital & Clinic, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breakthrough Bleeding appearing as the primary indexed condition, and to 2 interventions - of which remove ring if bleeding or spotting occurs more than 5 days is the first listed.
NCT00475553 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00475553 about?
NCT00475553 is a clinical study titled "Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing®". The purpose of this research study is to evaluate the best way to manage breakthrough spotting and bleeding during an extended use regimen of NuvaRing®. Ease of use and acceptability of a flexible regimen of NuvaRing® will also be evaluated. A comparison of cyclic mood symptoms, pelvic pain, and hea...
What is the current status of trial NCT00475553?
This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2006-05. Estimated completion is 2008-05.
What conditions does trial NCT00475553 study?
This clinical trial studies the following conditions: Breakthrough Bleeding, Breakthrough Spotting.
What interventions are being tested in trial NCT00475553?
The interventions under investigation include: remove ring if bleeding or spotting occurs more than 5 days (OTHER), If bleeding does not remove ring (OTHER).
Who is sponsoring clinical trial NCT00475553?
This trial is sponsored by Scott and White Hospital & Clinic, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00475553 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breakthrough Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.